Sarepta on Monday unveiled a small batch of positive data for one of the gene therapies it bought out last year, sketching a path toward a pivotal study in 2021 and helping bolster the company’s broader gene therapy ambitions.
The gene therapy, known as SRP-9003, is designed to treat a rare degenerative disorder called limb-girdle muscular dystrophy by boosting production of a protein patients are missing, called beta-sarcoglycan. It was part of a basket of treatments Sarepta acquired in its $165 million-buyout of Myonexus last year. The biotech already showed a low dose of the therapy could lead to some increased expression of the missing protein and some improved muscle function in 3 kids, but it was unclear how long those results would last or if a higher dose would lead to better results.
"industry" - Google News
June 08, 2020 at 06:47PM
https://ift.tt/2ARsW9o
When times got tough, the biopharma industry hit the Zoom button and kept things moving at a multibillion-dollar clip - Endpoints News
"industry" - Google News
https://ift.tt/2RrQtUH
https://ift.tt/2zJ3SAW
Bagikan Berita Ini
0 Response to "When times got tough, the biopharma industry hit the Zoom button and kept things moving at a multibillion-dollar clip - Endpoints News"
Post a Comment